With the maturity of peptide synthesis technology and the improvement of pharmaceutical preparation research and development technology, peptide drugs have attracted the attention of researchers at home and abroad. In clinical medicine, peptide drugs are mainly used to treat a variety of complex diseases such as diabetes and osteoporosis.
Compared with macromolecular proteins or antibody drugs, peptide drugs are more stable and have higher unit activity at room temperature. Peptide drugs are usually formed by separation and purification of 10 to 100 amino acid molecules after dehydration.
A peptide is an amino acid that is linked by peptide bonds through separation technology to form peptide drugs. It can be used in cardiovascular, muscle, skeletal, blood and other systems.
According to the report "Prevalence of Obesity and Related Complications in China: A Cross-sectional Real-World Study of 15.8 Million Adults" published in the academic journal "Diabetes, Obesity and Metabolism" in August 2023, among the studied population, 34.8% in China The population is overweight, and 14.1% of the population is obese.
Currently, a total of 13 GLP-1 peptide drugs have been approved for marketing worldwide.
Drug trials have shown that GLP-1 drugs(semaglutide injection) are not only beneficial to type I diabetes, weight loss, and cardiovascular disease, but also have positive effects on non-alcoholic steatohepatitis, metabolic disorders, Alzheimer's disease, Parkinson's disease, etc.
The popularity of weight loss medication such as weight loss injections has grown significantly around the world, showing the broad market potential of the new generation of weight-loss drugs. Popular drugs are expected to appear in this field in the future. In addition, global GLP-1 drug research and development is progressing rapidly, and various multi-target and oral preparations are being launched into clinical trials. Therefore, the peptide industry chain will usher in rapid development.
Reference
[1].BROWN E, WILDING J P H, BARBER T M, et al. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities[J]. Obes Rev, 2019, 20(6):816-828.
[2]. LEVIN P A, NGUYEN H, WITTBRODT E T, et al. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research[J]. Diabetes Metab Syndr Obes, 2017, 10:123-139.
